Breaking News

Roche Accelerates Phase III Actemra Trial in COVID-19

Receives $25 million in support from BARDA to evaluate safety and efficacy in severe COVID-19 pneumonia

By: Contract Pharma

Contract Pharma Staff

Roche will accelerate Actemra’s Phase III trial in COVID-19 patients with $25 million in support from the U.S. Biomedical Advanced Research and Development Authority (BARDA).

Actemra/RoActemra (tocilizumab), an anti-IL-6 receptor biologic currently approved to treat rheumatoid arthritis, is being evaluated in a randomized, double-blind, placebo-controlled Phase III trial in collaboration with BARDA, for safety and efficacy in hospitalized patients with severe COVID-19 pneumonia compared to placebo plus standard of care.

This is the first global study of Actemra/RoActemra in this setting with a target of approximately 330 patients globally, including the U.S. The primary and secondary endpoints include clinical status, mortality, mechanical ventilation and intensive care unit (ICU) variables.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters